Tenderwize
Retour à la recherche

Discount Contract for Golimumab

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 338 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-21 - Golimumab

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume information, making it difficult to assess potential business impact.

As an Open House discount contract, there is no guaranteed revenue; uptake depends on pharmacy substitution.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Supply of pharmaceutical products containing the active substance Golimumab
  • Conclusion of discount contracts under § 130a Abs. 8 SGB V with standardized terms and conditions
Afficher le résumé complet

Open House discount contract (Rabattvertrag) for the active substance Golimumab, administered by Techniker Krankenkasse (TK) on behalf of multiple German health insurance funds. Contract conclusion occurs under § 130a Abs. 8 SGB V with standardized terms, no exclusive rights, and a maximum duration of 12 months starting 01.08.2026, extendable by 12 months. This is an Open House procedure, not a public procurement subject to competition rules. No estimated value is provided.

Risques

No estimated value or volume information, making it difficult to assess potential business impact.

As an Open House discount contract, there is no guaranteed revenue; uptake depends on pharmacy substitution.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Pharmaceutical entrepreneur status (as per § 4 Abs. 18 AMG) for the offered medicinal product
  • Valid marketing authorization or entitlement to market the product under own name
  • Place of business in the AMG area, EU, or EEA

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not applicable for Open House procedure; all qualifying participants are accepted.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Discount Contract for Golimumab

Discount contract for the active substance Golimumab under an Open House procedure. Contract concluded with all eligible pharmaceutical entrepreneurs who meet the qualification requirements.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Jul 2026 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

Not applicable for Open House procedure; all qualifying participants are accepted.

Date limite

Deadline Jul 30, 2027

Détails de la procédure

Date de publication
07 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
389754-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3